JPMorgan raised the firm’s price target on Scholar Rock (SRRK) to $50 from $47 and keeps an Overweight rating on the shares. The firm updated the company’s model ahead of a potential launch of apitegromab. JPMorgan continues to recommend Scholar Rock shares in 2026, saying apitegromab should be approved with a broad label for spinal muscular atrophy. The analyst expects a strong launch in given the clinical data and high unmet need. The firm sees the drug growing to over $2B in worldwide sales over time.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRRK:
- Scholar Rock Eyes 2026 Launch Amid Regulatory Push
- Scholar Rock price target raised to $55 from $44 at Truist
- Scholar Rock price target raised to $58 from $51 at Piper Sandler
- Scholar Rock: Positive Regulatory Trajectory and Commercial Readiness for Apitegromab Support Buy Rating and Multi‑Billion‑Dollar SMA Potential
- Scholar Rock price target raised to $70 from $50 at BMO Capital